

Rheo Dx



THE PROBLEM

Currently, 112 million transfusions are administered per year, 20% of which are unnecessary.

This is an extra cost to the health system of more than 3.5 billion euros at a global level. The reason is that there is no specific method to control the number of transfusions that each patient requires, or how efficient these are once transfused.



THE SOLUTION

Our patented tech studies physical properties of blood, providing greater precision at lower cost compared to other methods of analysis.

Data obtained from measurements are processed in the cloud, where they can be precisely associated with the pathological conditions of the blood cells through the recognition of patterns, through artificial intelligence capabilities. This allows you to increase the diagnostic range without hardware changes.



THE PRODUCT

The connectivity of the device, its rapid and simple handling as well as its high portability confer a great versatility with a multitude of applications.

Primarily, diagnosing and monitoring of hematological disorders with a single drop of blood, both in hospitals and primary care as well as in the patient's home. Our device is remarkably versatile and is configured to deliver maximum precision diagnostics at extremely competitive prices.

MILESTONES

Founded
2018

Proof of Concept
2018


Patent Protection
2018, EU & USA

Clinical Validation
2019


CE Mark/ Market Launch
2020

POTENTIAL MARKET

Global market size: 60 Billion



FUNDING GOALS



KEY METRICS

0,5 €	Production cost
1	Blood drops needed
11%	European population prevalence
5 min	Time needed to carry out a test
8 €	Rheo Dx test price



COMPANY



www.rheodx.com

[@RheoDx](https://twitter.com/RheoDx)

[Rheo Dx](https://www.linkedin.com/company/rheodx)



FOUNDERS



Oliver Balcells

CEO



Samantha López

CCO



Joan Grasas

CRO



www.cimti.cat | info@cimti.cat

PROMOTER



WITH THE SUPPORT OF

